The present invention relates to modified or
polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or
increasing weight loss, treating
obesity and / or treating
metabolic syndrome utilizing the modified or
polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving
insulin sensitivity and
glycemic control, reducing
insulin levels and / or improving
leptin sensitivity utilizing the modified or
polymer conjugated MetAP2 inhibitors.